Preparation and immunogenic properties of a recombinant West Nile subunit vaccine

Michael M. Lieberman, David E. Clements, Steven Ogata, Gordon Wang, Gloria Corpuz, Teri Wong, Tim Martyak, Lynne Gilson, Beth Ann Coller, Julia Leung, Douglas M. Watts, Robert B. Tesh, Marina Siirin, Amelia Travassos da Rosa, Tom Humphreys, Carolyn Weeks-Levy

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

While several West Nile vaccines are being developed, none are yet available for humans. In this study aimed at developing a vaccine for humans, West Nile virus (WNV) envelope protein (E) and non-structural protein 1 (NS1) were produced in the Drosophila S2 cell expression system. The C-terminal 20% of the E protein, which contains the membrane anchor portion, was deleted, thus allowing for efficient secretion of the truncated protein (80E) into the cell culture medium. The proteins were purified by immunoaffinity chromatography (IAC) using monoclonal antibodies that were flavivirus envelope protein group specific (for the 80E) or flavivirus NS1 group specific (for NS1). The purified proteins were produced in high yield and used in conjunction with adjuvant formulations to vaccinate mice. The mice were tested for both humoral and cellular immune responses by a plaque reduction neutralization test and ELISA, and by lymphocyte proliferation and cytokine production assays, respectively. The results revealed that the 80E and the NS1 proteins induced both high-titered ELISA and neutralizing antibodies in mice. Splenocytes from immunized mice, cultured in vitro with the vaccine antigens as stimulants, showed excellent proliferation and production of cytokines (IFN-γ, IL-4, IL-5, and IL-10). The level of antigen-stimulated lymphocyte proliferation and cytokine production was comparable to the level obtained from mitogen (phytohemagglutinin or pokeweed) stimulation, indicating a robust cellular response as well. These findings are encouraging and warrant further in vivo studies to determine the protective efficacy of the WNV vaccine candidate.

Original languageEnglish (US)
Pages (from-to)414-423
Number of pages10
JournalVaccine
Volume25
Issue number3
DOIs
StatePublished - Jan 5 2007

Fingerprint

Subunit Vaccines
subunit vaccines
Proteins
proteins
vaccines
Flavivirus
cytokines
Vaccines
West Nile virus
mice
lymphocyte proliferation
Cytokines
West Nile Virus Vaccines
Phytolacca americana
Enzyme-Linked Immunosorbent Assay
enzyme-linked immunosorbent assay
Lymphocytes
Viral Envelope Proteins
antigens
Antigens

Keywords

  • Recombinant subunit vaccine
  • West Nile vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Lieberman, M. M., Clements, D. E., Ogata, S., Wang, G., Corpuz, G., Wong, T., ... Weeks-Levy, C. (2007). Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine, 25(3), 414-423. https://doi.org/10.1016/j.vaccine.2006.08.018

Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. / Lieberman, Michael M.; Clements, David E.; Ogata, Steven; Wang, Gordon; Corpuz, Gloria; Wong, Teri; Martyak, Tim; Gilson, Lynne; Coller, Beth Ann; Leung, Julia; Watts, Douglas M.; Tesh, Robert B.; Siirin, Marina; Travassos da Rosa, Amelia; Humphreys, Tom; Weeks-Levy, Carolyn.

In: Vaccine, Vol. 25, No. 3, 05.01.2007, p. 414-423.

Research output: Contribution to journalArticle

Lieberman, MM, Clements, DE, Ogata, S, Wang, G, Corpuz, G, Wong, T, Martyak, T, Gilson, L, Coller, BA, Leung, J, Watts, DM, Tesh, RB, Siirin, M, Travassos da Rosa, A, Humphreys, T & Weeks-Levy, C 2007, 'Preparation and immunogenic properties of a recombinant West Nile subunit vaccine', Vaccine, vol. 25, no. 3, pp. 414-423. https://doi.org/10.1016/j.vaccine.2006.08.018
Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine. 2007 Jan 5;25(3):414-423. https://doi.org/10.1016/j.vaccine.2006.08.018
Lieberman, Michael M. ; Clements, David E. ; Ogata, Steven ; Wang, Gordon ; Corpuz, Gloria ; Wong, Teri ; Martyak, Tim ; Gilson, Lynne ; Coller, Beth Ann ; Leung, Julia ; Watts, Douglas M. ; Tesh, Robert B. ; Siirin, Marina ; Travassos da Rosa, Amelia ; Humphreys, Tom ; Weeks-Levy, Carolyn. / Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. In: Vaccine. 2007 ; Vol. 25, No. 3. pp. 414-423.
@article{58be1af4a88f45fc8beaa2c623376c6e,
title = "Preparation and immunogenic properties of a recombinant West Nile subunit vaccine",
abstract = "While several West Nile vaccines are being developed, none are yet available for humans. In this study aimed at developing a vaccine for humans, West Nile virus (WNV) envelope protein (E) and non-structural protein 1 (NS1) were produced in the Drosophila S2 cell expression system. The C-terminal 20{\%} of the E protein, which contains the membrane anchor portion, was deleted, thus allowing for efficient secretion of the truncated protein (80E) into the cell culture medium. The proteins were purified by immunoaffinity chromatography (IAC) using monoclonal antibodies that were flavivirus envelope protein group specific (for the 80E) or flavivirus NS1 group specific (for NS1). The purified proteins were produced in high yield and used in conjunction with adjuvant formulations to vaccinate mice. The mice were tested for both humoral and cellular immune responses by a plaque reduction neutralization test and ELISA, and by lymphocyte proliferation and cytokine production assays, respectively. The results revealed that the 80E and the NS1 proteins induced both high-titered ELISA and neutralizing antibodies in mice. Splenocytes from immunized mice, cultured in vitro with the vaccine antigens as stimulants, showed excellent proliferation and production of cytokines (IFN-γ, IL-4, IL-5, and IL-10). The level of antigen-stimulated lymphocyte proliferation and cytokine production was comparable to the level obtained from mitogen (phytohemagglutinin or pokeweed) stimulation, indicating a robust cellular response as well. These findings are encouraging and warrant further in vivo studies to determine the protective efficacy of the WNV vaccine candidate.",
keywords = "Recombinant subunit vaccine, West Nile vaccine",
author = "Lieberman, {Michael M.} and Clements, {David E.} and Steven Ogata and Gordon Wang and Gloria Corpuz and Teri Wong and Tim Martyak and Lynne Gilson and Coller, {Beth Ann} and Julia Leung and Watts, {Douglas M.} and Tesh, {Robert B.} and Marina Siirin and {Travassos da Rosa}, Amelia and Tom Humphreys and Carolyn Weeks-Levy",
year = "2007",
month = "1",
day = "5",
doi = "10.1016/j.vaccine.2006.08.018",
language = "English (US)",
volume = "25",
pages = "414--423",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Preparation and immunogenic properties of a recombinant West Nile subunit vaccine

AU - Lieberman, Michael M.

AU - Clements, David E.

AU - Ogata, Steven

AU - Wang, Gordon

AU - Corpuz, Gloria

AU - Wong, Teri

AU - Martyak, Tim

AU - Gilson, Lynne

AU - Coller, Beth Ann

AU - Leung, Julia

AU - Watts, Douglas M.

AU - Tesh, Robert B.

AU - Siirin, Marina

AU - Travassos da Rosa, Amelia

AU - Humphreys, Tom

AU - Weeks-Levy, Carolyn

PY - 2007/1/5

Y1 - 2007/1/5

N2 - While several West Nile vaccines are being developed, none are yet available for humans. In this study aimed at developing a vaccine for humans, West Nile virus (WNV) envelope protein (E) and non-structural protein 1 (NS1) were produced in the Drosophila S2 cell expression system. The C-terminal 20% of the E protein, which contains the membrane anchor portion, was deleted, thus allowing for efficient secretion of the truncated protein (80E) into the cell culture medium. The proteins were purified by immunoaffinity chromatography (IAC) using monoclonal antibodies that were flavivirus envelope protein group specific (for the 80E) or flavivirus NS1 group specific (for NS1). The purified proteins were produced in high yield and used in conjunction with adjuvant formulations to vaccinate mice. The mice were tested for both humoral and cellular immune responses by a plaque reduction neutralization test and ELISA, and by lymphocyte proliferation and cytokine production assays, respectively. The results revealed that the 80E and the NS1 proteins induced both high-titered ELISA and neutralizing antibodies in mice. Splenocytes from immunized mice, cultured in vitro with the vaccine antigens as stimulants, showed excellent proliferation and production of cytokines (IFN-γ, IL-4, IL-5, and IL-10). The level of antigen-stimulated lymphocyte proliferation and cytokine production was comparable to the level obtained from mitogen (phytohemagglutinin or pokeweed) stimulation, indicating a robust cellular response as well. These findings are encouraging and warrant further in vivo studies to determine the protective efficacy of the WNV vaccine candidate.

AB - While several West Nile vaccines are being developed, none are yet available for humans. In this study aimed at developing a vaccine for humans, West Nile virus (WNV) envelope protein (E) and non-structural protein 1 (NS1) were produced in the Drosophila S2 cell expression system. The C-terminal 20% of the E protein, which contains the membrane anchor portion, was deleted, thus allowing for efficient secretion of the truncated protein (80E) into the cell culture medium. The proteins were purified by immunoaffinity chromatography (IAC) using monoclonal antibodies that were flavivirus envelope protein group specific (for the 80E) or flavivirus NS1 group specific (for NS1). The purified proteins were produced in high yield and used in conjunction with adjuvant formulations to vaccinate mice. The mice were tested for both humoral and cellular immune responses by a plaque reduction neutralization test and ELISA, and by lymphocyte proliferation and cytokine production assays, respectively. The results revealed that the 80E and the NS1 proteins induced both high-titered ELISA and neutralizing antibodies in mice. Splenocytes from immunized mice, cultured in vitro with the vaccine antigens as stimulants, showed excellent proliferation and production of cytokines (IFN-γ, IL-4, IL-5, and IL-10). The level of antigen-stimulated lymphocyte proliferation and cytokine production was comparable to the level obtained from mitogen (phytohemagglutinin or pokeweed) stimulation, indicating a robust cellular response as well. These findings are encouraging and warrant further in vivo studies to determine the protective efficacy of the WNV vaccine candidate.

KW - Recombinant subunit vaccine

KW - West Nile vaccine

UR - http://www.scopus.com/inward/record.url?scp=33845224427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845224427&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.08.018

DO - 10.1016/j.vaccine.2006.08.018

M3 - Article

VL - 25

SP - 414

EP - 423

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -